阿司匹林与P2Y12反应测定在创伤性脑损伤中判断抗血小板药物对血小板反应性作用的效用
该单中心前瞻性队列研究纳入2010年11月至2015年1月就诊的317例创伤性脑损伤患者,入院即刻用阿司匹林和P2Y12反应单位测定评估血小板反应性。有阿司匹林使用史者平均阿司匹林反应单位为456±67,88%显示治疗性血小板抑制;氯吡格雷平均P2Y12反应单位为191±70,77%显示治疗性反应。作者结论认为多达四分之一的抗血小板治疗患者无血小板功能障碍,需进一步研究制定指南。
要点
- 有阿司匹林使用史者平均阿司匹林反应单位为456±67,88%达治疗性血小板抑制。
- 氯吡格雷使用者平均P2Y12反应单位为191±70,77%显示治疗性反应。
- 多达四分之一的抗血小板治疗患者无血小板功能障碍。
核心结论
- 快速测定抗血小板功能显示多达四分之一的抗血小板治疗患者无血小板功能障碍。
- 需进一步研究制定这些测定用于指导创伤性脑损伤中血小板输注的指南。
研究设计与样本
- 单中心前瞻性队列研究,纳入2010年11月至2015年1月就诊于本机构且有创伤性脑损伤临床病史的患者。
- 入院即刻测定血清血小板反应性水平,使用阿司匹林和P2Y12反应单位测定,结果报告为阿司匹林反应单位和P2Y12反应单位。
- 分析样本317例,其中87%为轻度创伤性脑损伤、7%为中度、6%为重度,平均年龄71.5岁。
主要发现
- 有阿司匹林使用史者平均阿司匹林反应单位为456±67(范围350-659),88%显示治疗性血小板抑制。
- 氯吡格雷使用者平均P2Y12反应单位为191±70(范围51-351),77%显示治疗性反应。
- 报告了测定结果与临床病史之间的一致性以及不同类型抗血小板治疗之间测定结果的差异。
局限性
- 需进一步研究制定这些测定用于指导创伤性脑损伤中血小板输注的指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Premorbid antithrombotic medication may worsen intracranial injury and outcome after traumatic brain injury (TBI). Routine laboratory tests are insufficient to evaluate platelet activity. OBJECTIVE: To profile the spectrum of platelet inhibition, as measured by aspirin and P2Y12 response unit assays, in a TBI population on antiplatelet therapy. METHODS: This single-center, prospective cohort study included patients presenting to our institution between November 2010 and January 2015 with a clinical history of TBI. Serum platelet reactivity levels were determined immediately on admission and analyzed using the aspirin and P2Y12 response unit assays; test results were reported as aspirin response units and P2Y12 response units. We report congruence between assay results and clinical history as well as differences in assay results between types of antiplatelet therapy. RESULTS: A sample of 317 patients was available for analysis, of which 87% had experienced mild TBI, 7% moderate, and 6% severe; the mean age was 71.5 years. The mean aspirin response units in patients with a history of any aspirin use was 456 ± 67 (range, 350-659), with 88% demonstrating therapeutic platelet inhibition. For clopidogrel, the mean P2Y12 response unit was 191 ± 70 (range, 51-351); 77% showed therapeutic response. CONCLUSION: Rapid measurement of antiplatelet function using the aspirin and P2Y12 response assays indicated as many as one fourth of patients on antiplatelet therapy do not have platelet dysfunction. Further research is required to develop guidelines for the use of these assays to guide platelet transfusion in the setting of TBI.
引用
- Parry PV, Choi PA, Bauer JS, et al. Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury. Neurosurgery. 2017. PMID: 28362884. doi:10.1227/NEU.0000000000001406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。